Anti-Prostate Cancer Agents walks the readers through the anti-prostate cancer drug development pipeline from early discovery/design to clinical studies/applications. This book covers discovery/design, synthetic studies, preclinical evaluation, mechanism of action, structure-activity relationships, clinical studies/applications of anti-prostate cancer agents.
This book provides insight on how the design and discovery process of anti-prostate cancer agents have evolved from androgen deprivation therapy to current androgen receptor antagonists/degraders. So far, no book focusing on the topic has been published.
1. Introduction: Overview of Prostate Cancer? ???
2.?Why has one got prostate cancer?
3. Androgen Deprivation Therapy
4. Anti-prostate cancer agents interacting with topoisomerase
5. Microtubule-Stabilizing Compounds as Anti-Prostate Cancer Agents
6. Androgen/Androgen Receptor Signaling Pathway and Prostate Cancer?
7. Anti-Prostate Cancer Agents Suppressing Androgen Biosynthesis?
8. First Generation Nonsteroidal Androgen Receptor Antagonists?
9. Second Generation Nonsteroidal Androgen Receptor Antagonists
10. Anti-Prostate Cancer Agents Interacting with N-Terminal Domain of Androgen Receptor
11. Androgen Receptor Degraders as Anti-Prostate Cancer Agents
12. Radiotherapeutics for treatment of Prostate Cancer
13. Immunotherapy for Prostate Cancer
14. Radiosensitizer for prostate cancer?
15. Anti-Prostate Cancer Agents Targeting Prostate-Specific Membrane Antigen
16. Anti-Prostate Cancer Agents Targeting Poly(ADP-Ribose)Polymerase
17. Combined Anti-Prostate Cancer Agents
18. Future Directions?
Dr Qiao-Hong Chen received her PhD degree in Medicinal Chemistry from Sichuan University, China. Appointed as a Lecturer in 2001, She was promoted to the position of Full Professor in 2003 at Sichuan University. She was a Postdoctoral Fellow for three years at the University of Alberta in Canada and a Senior Research Fellow for six years at Virginia Tech. She joined Fresno State in 2012. Her research interests focus on natural products-based anticancer agents. She has published 152 peer-reviewed scientific publications, as well as 5 book chapters.
